U.S., April 15 -- ClinicalTrials.gov registry received information related to the study (NCT07527650) titled 'Study to Evaluate HM15275 in Subjects With Type 2 Diabetes Mellitus' on April 07.
Brief Summary: This study is a Phase 2 clinical trial to evaluate the efficacy, safety, and tolerability of HM15275 in subjects with type 2 diabetes mellitus over 36 weeks.
Study Start Date: May, 2026
Study Type: INTERVENTIONAL
Condition:
Type 2 Diabetes Mellitus
T2DM
Intervention:
DRUG: HM15275
HM15275 is a sterile solution for subcutaneous injection, supplied pre-filled syringes.
DRUG: Placebo of HM15275
A sterile, matching solution supplied in pre-filled syringes.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Hanmi Pharmaceutical Compa...